Growth and Expansion Biomay has a track record of facility expansion and capacity growth in Vienna, signaling readiness to scale for larger GMP plasmid DNA, mRNA, and recombinant protein production opportunities for new clients and collaborations.

Catalog mRNA and Nuclease Recent launches of mRNA-encoded spCas9 and FDA-grade CRISPR/Cas9 nuclease create cross-selling opportunities for genome editing and therapeutic development partners seeking ready-to-use, quality-assured reagents with reliable supply.

Quality and Reliability Position Biomay as a flexible, quality-driven GMP manufacturer with end-to-end capabilities from gene construction to market supply, appealing to biotech and pharma teams prioritizing compliance, traceability, and dependable delivery.

Strategic Partnerships Past collaborations with BioNTech and industry partners indicate a propensity for joint development and supply chain support, suggesting avenues for new partnerships in mRNA therapeutics, vaccines, and gene-editing products.

Small-to-Mid Market Focus With revenue in the 1–10M range and a mid-sized employee base, Biomay is well positioned to win pilot projects, toll manufacturing, and contract manufacturing opportunities from mid-market biotech firms seeking scalable plasmid DNA, mRNA, and recombinant protein production.